S100A4 and colorectal carcinoma: S100A4 was assessed in a previous meta-analysis, published in 2013, in 2,615 patients from 13 studies, in stage II–IV CRC, which found a significant association with worse OS (HR 1.90, 95% CI 1.58–2.29, eight studies) and DFS (HR 2.16, 95% CI 1.53–3.05, three studies) (50).